From Nanotechnology to Nanomedicine: Applications to Cancer Research
R. Seigneuric, L. Markey, D. S.A. Nuyten, C. Dubernet, C. T.A. Evelo, E. Finot and C. Garrido
Affiliation: Nanosciences Department Carnot Institute of Burgundy, CNRS-UMR 5209, 9, Avenue Alain Savary, BP 47870 21078 DIJON Cedex, France.
Scientific advances have significantly improved the practice of medicine by providing objective and quantitative means for exploring the human body and disease states. These innovative technologies have already profoundly improved disease detection, imaging, treatment and patient follow-up. Todays analytical limits are at the nanoscale level (one-billionth of a meter) enabling a detailed exploration at the level of DNA, RNA, proteins and metabolites which are in fact nano-objects. This translational review aims at integrating some recent advances from micro- and nano-technologies with high potential for improving daily oncology practice.
Keywords: Nanomedicine, circulating tumour cell, nanoparticle, EPR effect, Nanotechnology, Enzymes, Antibodies, Blood-brain barrier, Nano-objects, Nanospheres, Nanotubes, Nanorods, Nanowires, Biosensors, Biomolecules, Biomarkers, Metastases, Clonogenic cancer cells, Epithelial Cell Adhesion Molecule, EpCAM(CD326), Antigen, Antibody, immunohistochemistry, Fluorescence microscope, CTC chip, Aptamers, Aptasensors, Nanovectorization, Surface plasmon resonance, Ellipsometry, SPR imaging, Microfluidics, Microtechnologies, Electrophoresis, ELISA, Labs-on-chip, Point-of-care devices, Drug delivery, Radiotherapy, Chemotherapy, Pharmacokinetics, Reticuloendothelial system, Immune system, Nanoparticles, Vectorization, Doxorubicin, Anthracyclins, Cardiotoxicity, Myelosuppression, Paclitaxel, Docetaxel, DNA topoisomerase, XMT-1001, Camptothecin, Tumor necrosis, Factor alpha, Reactive oxygen species
Rights & PermissionsPrintExport